Drug intelligence / Profile preview

tozinameran + famtozinameran

Development stage: Approved
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The COVID-19 bivalent mRNA vaccine (specifically the Pfizer-BioNTech version BNT162b2) is a nucleoside-modified messenger RNA (mRNA) vaccine designed to provide broad protection against SARS-CoV-2. It contains two mRNA components: one encoding the spike protein of the original (wild-type) SARS-CoV-2 strain and another encoding the spike protein of the Omicron BA.4/BA.5 subvariants. By delivering the genetic instructions for these proteins, the vaccine induces the host's cells to produce the antigens, triggering a robust immune response including the production of neutralizing antibodies and T-cell activation. It is primarily used as a booster dose to enhance immunity against evolving variants.

Brand names: Comirnaty Original/Omicron BA.4-5
Other names: COVID-19 bivalent mRNA vaccineCOVID19 bivalent mRNA vaccineCOVID 19 bivalent mRNA vaccinePfizer-BioNTech COVID-19 Vaccine, BivalentBNT162b2 BivalentBNT-162b2 BivalentBNT 162b2 Bivalent

Targets

BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)

Beyond the preview

Go deeper on tozinameran + famtozinameran.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tozinameran + famtozinameran.

Explore the full profile